[
    {
        "molecule_name": "Compound 10",
        "protein_target_name": "ERα",
        "binding_metric": "EC50",
        "value": "1.8",
        "unit": "nmol/L",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n(7α,16β,17α)-3,17-dihydroxy-7-propyl-16,24-cyclo-19,21-dinorchola-1,3,5(10)-trien-22-one (Compound 10) is unique in having a combined partial ER/partial PR (ant)agonistic profile with an EC50 of 1.8 nmol/L for ERα and of 3.8 nmol/L for progesterone receptor B (PR-B).\n(7α,16β,17α)-3,17-dihydroxy-7-propyl-16,24-cyclo-19,21-dinorchola-1,3,5(10)-trien-22-one is an antagonist for the androgen receptor (AR) with an IC50 of 125 nM.\nERα ago EC50; eff1.8 nM; 0.63\nERα ant IC50; anteff10.0 nM; 0.47\nERβ ago EC50; eff>10,000 nM\nERβ ant IC50; anteff8.4 nM; 0.83\nPR-B ago EC50; eff3.8 nM; 0.49\nPR-B ant IC50; anteff3.7 nM; 0.55\nPR-A ago EC50; eff30.0 nM; 0.46\nPR-A ant IC50; anteff27.0 nM; 0.54\nIn a 4-week phase I study, female human volunteers were exposed to the compound (7α,16β,17α)-3,17-dihydroxy-7-propyl-16,24-cyclo-19,21-dinorchola-1,3,5(10)-trien-22-one (Compound 10) at blood plasma level with Cmax of 16 nM, endometrial biopsies were obtained on day 29. \nThe minimal active dose (MAD) for ovulation inhibition upon oral dosing in gelatine/mannitol was established at <=0.1 mg/kg per day."
    },
    {
        "molecule_name": "Compound 10",
        "protein_target_name": "PR-B",
        "binding_metric": "EC50",
        "value": "3.8",
        "unit": "nmol/L",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n(7α,16β,17α)-3,17-dihydroxy-7-propyl-16,24-cyclo-19,21-dinorchola-1,3,5(10)-trien-22-one (Compound 10) is unique in having a combined partial ER/partial PR (ant)agonistic profile with an EC50 of 1.8 nmol/L for ERα and of 3.8 nmol/L for progesterone receptor B (PR-B).\n(7α,16β,17α)-3,17-dihydroxy-7-propyl-16,24-cyclo-19,21-dinorchola-1,3,5(10)-trien-22-one is an antagonist for the androgen receptor (AR) with an IC50 of 125 nM.\nERα ago EC50; eff1.8 nM; 0.63\nERα ant IC50; anteff10.0 nM; 0.47\nERβ ago EC50; eff>10,000 nM\nERβ ant IC50; anteff8.4 nM; 0.83\nPR-B ago EC50; eff3.8 nM; 0.49\nPR-B ant IC50; anteff3.7 nM; 0.55\nPR-A ago EC50; eff30.0 nM; 0.46\nPR-A ant IC50; anteff27.0 nM; 0.54\nIn a 4-week phase I study, female human volunteers were exposed to the compound (7α,16β,17α)-3,17-dihydroxy-7-propyl-16,24-cyclo-19,21-dinorchola-1,3,5(10)-trien-22-one (Compound 10) at blood plasma level with Cmax of 16 nM, endometrial biopsies were obtained on day 29. \nThe minimal active dose (MAD) for ovulation inhibition upon oral dosing in gelatine/mannitol was established at <=0.1 mg/kg per day."
    },
    {
        "molecule_name": "Compound 10",
        "protein_target_name": "AR",
        "binding_metric": "IC50",
        "value": "125",
        "unit": "nM",
        "raw_mentions": "Here are the extracted sentences/rows that meet the criteria:\n\n(7α,16β,17α)-3,17-dihydroxy-7-propyl-16,24-cyclo-19,21-dinorchola-1,3,5(10)-trien-22-one (Compound 10) is unique in having a combined partial ER/partial PR (ant)agonistic profile with an EC50 of 1.8 nmol/L for ERα and of 3.8 nmol/L for progesterone receptor B (PR-B).\n(7α,16β,17α)-3,17-dihydroxy-7-propyl-16,24-cyclo-19,21-dinorchola-1,3,5(10)-trien-22-one is an antagonist for the androgen receptor (AR) with an IC50 of 125 nM.\nERα ago EC50; eff1.8 nM; 0.63\nERα ant IC50; anteff10.0 nM; 0.47\nERβ ago EC50; eff>10,000 nM\nERβ ant IC50; anteff8.4 nM; 0.83\nPR-B ago EC50; eff3.8 nM; 0.49\nPR-B ant IC50; anteff3.7 nM; 0.55\nPR-A ago EC50; eff30.0 nM; 0.46\nPR-A ant IC50; anteff27.0 nM; 0.54\nIn a 4-week phase I study, female human volunteers were exposed to the compound (7α,16β,17α)-3,17-dihydroxy-7-propyl-16,24-cyclo-19,21-dinorchola-1,3,5(10)-trien-22-one (Compound 10) at blood plasma level with Cmax of 16 nM, endometrial biopsies were obtained on day 29. \nThe minimal active dose (MAD) for ovulation inhibition upon oral dosing in gelatine/mannitol was established at <=0.1 mg/kg per day."
    }
]